BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 19301721)

  • 1. Human telomerase reverse transcriptase (hTERT) expression in borderline ovarian tumors: an immunohistochemical study.
    Tantbirojn P; Triratanachat S; Trivijitsilp P; Niruthisard S
    J Med Assoc Thai; 2009 Mar; 92(3):308-14. PubMed ID: 19301721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical detection of human telomerase reverse transcriptase (hTERT) and c-kit in serous ovarian carcinoma: a clinicopathologic study.
    Brustmann H
    Gynecol Oncol; 2005 Sep; 98(3):396-402. PubMed ID: 16005054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
    Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
    Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methylation status and expression of human telomerase reverse transcriptase in ovarian and cervical cancer.
    Widschwendter A; Müller HM; Hubalek MM; Wiedemair A; Fiegl H; Goebel G; Mueller-Holzner E; Marth C; Widschwendter M
    Gynecol Oncol; 2004 May; 93(2):407-16. PubMed ID: 15099954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclooxygenase-2 expression in borderline ovarian tumors.
    Ferrandina G; Zannoni GF; Ranelletti FO; Legge F; Gessi M; Salutari V; Gallotta V; Lauriola L; Scambia G
    Gynecol Oncol; 2004 Oct; 95(1):46-51. PubMed ID: 15385109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human telomerase reverse transcriptase expression in ovarian tumors.
    Maraei AA; Hatta AZ; Shiran MS; Tan GC
    Indian J Pathol Microbiol; 2012; 55(2):187-91. PubMed ID: 22771641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vascular endothelial growth factor expression in serous ovarian carcinoma: relationship with topoisomerase II alpha and prognosis.
    Brustmann H
    Gynecol Oncol; 2004 Oct; 95(1):16-22. PubMed ID: 15385105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidermal growth factor receptor expression in serous ovarian carcinoma: an immunohistochemical study with galectin-3 and cyclin D1 and outcome.
    Brustmann H
    Int J Gynecol Pathol; 2008 Jul; 27(3):380-9. PubMed ID: 18580315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Serum level and expression of vascular epithelial growth factor in ovarian epithelial carcinoma].
    Sun LX; Wu Y; Han HQ; Wang QH
    Ai Zheng; 2003 Jan; 22(1):58-61. PubMed ID: 12561438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vascular endothelial growth factor expression in serous ovarian carcinoma: relationship with high mitotic activity and high FIGO stage.
    Brustmann H; Naudé S
    Gynecol Oncol; 2002 Jan; 84(1):47-52. PubMed ID: 11748975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The telomerase activity and expression of hTERT gene can serve as indicators in the anti-cancer treatment of human ovarian cancer.
    Sun PM; Wei LH; Luo MY; Liu G; Wang JL; Mustea A; Könsgen D; Lichtenegger W; Sehouli J
    Eur J Obstet Gynecol Reprod Biol; 2007 Feb; 130(2):249-57. PubMed ID: 16519988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Correlation of DPPIV expression with clinicopathological features and prognosis in epithelial ovarian carcinoma].
    Zhang MZ; Qiao YH; Suo ZH
    Zhonghua Zhong Liu Za Zhi; 2008 Nov; 30(11):848-52. PubMed ID: 19173831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progressive loss of selenium-binding protein 1 expression correlates with increasing epithelial proliferation and papillary complexity in ovarian serous borderline tumor and low-grade serous carcinoma.
    Zhang C; Wang YE; Zhang P; Liu F; Sung CJ; Steinhoff MM; Quddus MR; Lawrence WD
    Hum Pathol; 2010 Feb; 41(2):255-61. PubMed ID: 19896693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Poly(adenosine diphosphate-ribose) polymerase expression in serous ovarian carcinoma: correlation with p53, MIB-1, and outcome.
    Brustmann H
    Int J Gynecol Pathol; 2007 Apr; 26(2):147-53. PubMed ID: 17413981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Placental leucine aminopeptidase (P-LAP) and glucose transporter 4 (GLUT4) expression in benign, borderline, and malignant ovarian epithelia.
    Shibata K; Kajiyama H; Mizokami Y; Ino K; Nomura S; Mizutani S; Terauchi M; Kikkawa F
    Gynecol Oncol; 2005 Jul; 98(1):11-8. PubMed ID: 15907336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-time quantitative analysis for human telomerase reverse transcriptase mRNA and human telomerase RNA component mRNA expressions as markers for clinicopathologic parameters in urinary bladder cancer.
    Takihana Y; Tsuchida T; Fukasawa M; Araki I; Tanabe N; Takeda M
    Int J Urol; 2006 Apr; 13(4):401-8. PubMed ID: 16734859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Correlation of hK6 expression with clinicopathological features and prognosis in epithelial ovarian cancer].
    Hu CJ; Zhang F; Chen YJ; Sun XM; Zheng JF
    Zhonghua Zhong Liu Za Zhi; 2009 Jul; 31(7):520-3. PubMed ID: 19950700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA fragmentation factor (DFF45): expression and prognostic value in serous ovarian cancer.
    Brustmann H
    Pathol Res Pract; 2006; 202(10):713-20. PubMed ID: 16962250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human telomerase reverse transcriptase expression in colorectal tumors: correlations with immunohistochemical expression and clinicopathologic features.
    Simsek BC; Pehlivan S; Karaoglu A
    Ann Diagn Pathol; 2010 Dec; 14(6):413-7. PubMed ID: 21074689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclooxygenase 2 expression in serous tumors of the ovary.
    Singhal PK; Spiegel G; Driscoll D; Odunsi K; Lele S; Rodabaugh KJ
    Int J Gynecol Pathol; 2005 Jan; 24(1):62-6. PubMed ID: 15626918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.